Keywords: Novartis, Ruxolitinib, Incyte, Myelofibrosis, Blood cancer

Novartis blood cancer drug ruxolitinib meets Ph III endpoint

Article | 16 March 2011

Print This

Swiss drug major Novartis (NOVN: VX) revealed yesterday that it expects to file for approval in the second quarter of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in